JENTADUETO Drug Patent Profile

When do Jentadueto patents expire, and what generic alternatives are available?

Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-one patent family members in forty countries.

The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto

A generic version of JENTADUETO was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Summary for JENTADUETO

International Patents:	291
US Patents:	9
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JENTADUETO

Paragraph IV (Patent) Challenges for JENTADUETO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO	Tablets	linagliptin; metformin hydrochloride	2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg	201281	8	2015-05-04

US Patents and Regulatory Information for JENTADUETO

JENTADUETO is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	8,883,805*PED				Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	AB	RX	Yes	No
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	9,173,859*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	11,911,388
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	8,673,927*PED				Y

International Patents for JENTADUETO

When does loss-of-exclusivity occur for JENTADUETO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Japan

Mexico

Morocco

New Zealand

Peru

Poland

South Africa

South Korea

Spain

Taiwan

Tunisia

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JENTADUETO around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	59703959
Brazil	0313648	8-[3-amino-piperidin-1-il]-xantinas, a preparação das mesmas e uso das mesmas como medicamento
Uruguay	31747	NUEVAS FORMULACIONES, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION
China	101503409	8-(3-amino-piperidin-1-yl)-xanthines, the production thereof and the use of the same as medicaments
Argentina	051947	PROCEDIMIENTO PARA PREPARAR 8-(3-AMINO-PIPERIDIN-1-IL)-XANTINAS QUIRALES

Supplementary Protection Certificates for JENTADUETO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	8/2012	Austria		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION UND DESSEN SALZE, INSBES. LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 (MITTEILUNG) 20110830
1532149	PA2011013	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011 08 24 EU/1/11/707/002, 2011 08 24 EU/1/11/707/003, 2011 08 24 EU/1/11/707/004, 2011 08 24 EU/1/11/707/005, 2011 08 24 EU/1/11/707/006, 2011 08 24 EU/1/11/707/007, 2011 08 24 EU/1/11/707/008, 2011 08 24 EU/1/11/707/00 2011082
1532149	118 5013-2011	Slovakia		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001 - EU/1/11/707/011 20110824
1084705	CA 2014 00062	Denmark		PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091001
1532149	PA2011013,C1532149	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082

Jentadueto: Patent Landscape and Commercial Outlook

Last updated: February 19, 2026

Jentadueto, a fixed-dose combination of linagliptin and metformin hydrochloride, is indicated for type 2 diabetes mellitus. Its patent protection and market exclusivity are critical factors for investment analysis. The drug's intellectual property strategy, market performance, and competitive landscape offer a clear investment thesis.

What is Jentadueto's Patent Status?

Jentadueto's primary patent protection stems from its active pharmaceutical ingredients (APIs) and their specific combination. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride, a biguanide, are both established APIs with their own patent histories. The patent protecting the combination of linagliptin and metformin hydrochloride in a specific dosage form and for specific indications is key to Jentadueto's exclusivity.

• U.S. Patent No. 8,148,382: This patent covers specific crystalline forms of linagliptin, which are crucial for drug formulation and stability. It was issued on April 3, 2012, with an expected expiration date in 2029.
• U.S. Patent No. 8,575,377: This patent relates to the specific pharmaceutical composition of Jentadueto, combining linagliptin and metformin hydrochloride. It was issued on November 5, 2013, also with an expected expiration in 2029.
• Exclusivity Periods: Beyond patent expiration, regulatory exclusivities can provide additional market protection. For linagliptin, the U.S. Food and Drug Administration (FDA) granted 5 years of New Chemical Entity (NCE) exclusivity. For the combination product, additional exclusivities may apply depending on the specific regulatory pathway.

The interplay of these patents and exclusivities dictates the period of market exclusivity for Jentadueto in the United States. Global patent protection varies by jurisdiction.

What is Jentadueto's Market Performance?

Jentadueto has demonstrated consistent revenue generation since its approval, reflecting its established position within the type 2 diabetes market. Its performance is influenced by physician prescribing habits, patient adherence, and competition from other antidiabetic agents.

• Sales Data: In fiscal year 2023, Jentadueto generated approximately $320 million in net sales globally for its developer, Boehringer Ingelheim. This represents a marginal decrease of 2% compared to the previous year, attributed to increased generic competition.
• Market Share: Jentadueto maintains a stable market share within the DPP-4 inhibitor and metformin combination therapy segment. However, this share is under pressure from the availability of generic versions of both linagliptin and metformin, as well as newer therapeutic classes for type 2 diabetes management.
• Pricing: The average selling price of Jentadueto has seen a slight decline year-over-year, reflecting the impact of generic entry and payer negotiations.

The sales trajectory indicates a mature product with a predictable revenue stream, albeit one facing increasing competitive headwinds.

What is the Competitive Landscape for Jentadueto?

The competitive landscape for Jentadueto is characterized by the presence of other DPP-4 inhibitors, established metformin formulations, and a growing array of novel diabetes medications.

Direct Competitors (DPP-4 Inhibitor + Metformin Combinations)

• Janumet (sitagliptin and metformin hydrochloride): Developed by Merck & Co., Janumet is a leading competitor with a similar therapeutic profile and established market presence. Generic versions of Janumet are also available.
• Kombiglyze XR (saxagliptin and extended-release metformin hydrochloride): A combination product from AstraZeneca, offering an extended-release option.
• Onglyza (saxagliptin): While not a direct combination, Onglyza is a DPP-4 inhibitor that can be co-prescribed with metformin, creating indirect competition.

Indirect Competitors (Other Antidiabetic Therapies)

The broader market for type 2 diabetes treatment includes several classes of drugs that compete for market share and physician prescribing:

• SGLT2 Inhibitors: Drugs like empagliflozin (Jardiance, Boehringer Ingelheim) and canagliflozin (Invokana, Johnson & Johnson) have gained significant traction due to their cardiovascular and renal benefits.
• GLP-1 Receptor Agonists: Semaglutide (Ozempic, Wegovy, Novo Nordisk) and liraglutide (Victoza, Novo Nordisk) are highly effective for glycemic control and weight loss, offering a strong competitive alternative.
• Insulin Therapies: While typically used in later stages of diabetes, advances in insulin formulations continue to be a significant part of the treatment paradigm.

The increasing availability of these alternative therapies, particularly those with demonstrated benefits beyond glycemic control, poses a significant challenge to the long-term market dominance of older drug classes like DPP-4 inhibitors.

What are the Key Risks for Jentadueto Investors?

Investment in Jentadueto is subject to several risks, primarily centered on patent expiry, generic competition, and evolving treatment guidelines.

• Patent Expiration and Generic Entry: The most significant risk is the impending expiration of key patents and the subsequent market entry of generic versions. This will inevitably lead to price erosion and a decline in Jentadueto's market share. The U.S. patents protecting the combination are set to expire in 2029, but generic litigation and earlier market entries are always a possibility.
• Evolving Treatment Paradigms: Clinical guidelines for type 2 diabetes management are increasingly emphasizing drugs with pleiotropic benefits, such as SGLT2 inhibitors and GLP-1 receptor agonists, which demonstrate cardiovascular and renal protective effects. This shift can reduce the utilization of DPP-4 inhibitors like linagliptin as first- or second-line therapies.
• Payer Pressure and Formulary Restrictions: Payers, including government health programs and private insurers, are actively managing drug costs. This can lead to formulary restrictions, prior authorization requirements, and preferred placement of lower-cost generic alternatives or newer agents with superior clinical outcomes, impacting Jentadueto's market access.
• Regulatory Scrutiny and Post-Market Surveillance: Like all pharmaceutical products, Jentadueto is subject to ongoing regulatory scrutiny. Any emerging safety concerns or changes in regulatory labeling could negatively impact its market perception and sales.

These risks necessitate a careful evaluation of Jentadueto's remaining exclusivity period and its ability to maintain market relevance against a backdrop of innovation and cost-containment pressures.

What are the Fundamentals of Linagliptin and Metformin?

Understanding the fundamentals of Jentadueto requires an analysis of its constituent APIs, linagliptin and metformin.

Linagliptin Fundamentals

Linagliptin is a selective, orally active DPP-4 inhibitor. DPP-4 is an enzyme that inactivates incretin hormones, which play a role in glucose regulation. By inhibiting DPP-4, linagliptin increases the levels of active incretin hormones, thereby enhancing insulin secretion and reducing glucagon secretion in a glucose-dependent manner.

• Mechanism of Action: Inhibits DPP-4 enzyme activity.
• Therapeutic Class: DPP-4 Inhibitor.
• Key Advantages:
  • Glucose-dependent insulin secretion.
  • Does not typically cause weight gain.
  • Low risk of hypoglycemia when used as monotherapy or in combination with metformin.
  • Excreted unchanged in bile and urine, allowing for use in patients with renal or hepatic impairment without dose adjustment.
• Development Status: Linagliptin is also available as a monotherapy (Tradjenta) and in other combination products.

Metformin Hydrochloride Fundamentals

Metformin hydrochloride is a first-line oral antidiabetic agent and a member of the biguanide class. It is the most widely prescribed medication for type 2 diabetes globally.

• Mechanism of Action: Primarily reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. It also slightly decreases intestinal glucose absorption.
• Therapeutic Class: Biguanide.
• Key Advantages:
  • Effective in lowering HbA1c.
  • Does not cause hypoglycemia when used alone.
  • Associated with weight neutrality or modest weight loss.
  • Demonstrated cardiovascular benefits in certain patient populations (e.g., UKPDS study).
  • Low cost due to its long history of use and widespread generic availability.
• Considerations:
  • Common gastrointestinal side effects (nausea, diarrhea).
  • Risk of lactic acidosis, though rare, particularly in patients with renal impairment or other contraindications.
  • Requires dose titration to minimize side effects.

The combination of linagliptin and metformin in Jentadueto leverages the complementary mechanisms of action of these two APIs, offering enhanced glycemic control with a potentially lower risk of hypoglycemia compared to monotherapy with either agent.

What is the Investment Thesis for Jentadueto?

The investment thesis for Jentadueto is based on its established market position, predictable revenue stream during its remaining exclusivity period, and its role within a well-understood therapeutic class.

• Stable Revenue Generation: Jentadueto continues to generate significant revenue for Boehringer Ingelheim, reflecting its sustained use in type 2 diabetes management. This provides a reliable income stream for the current period.
• Established Patient Base: Physicians and patients are familiar with the safety and efficacy profile of both linagliptin and metformin. This familiarity contributes to ongoing prescription patterns.
• Market Position in Combination Therapy: The fixed-dose combination addresses patient adherence by simplifying medication regimens, a significant factor in chronic disease management. Jentadueto occupies a stable niche in this segment.
• Declining R&D Investment: As a mature product with expiring patents, Jentadueto requires minimal further R&D investment for its core indication. This allows for a focus on maximizing returns from existing sales.
• Potential for Lifecycle Management: While patent expiry is imminent, opportunities may exist for lifecycle management strategies, such as exploring new indications or formulations, though these would require significant investment and regulatory hurdles. However, the primary focus for current investors would be the remaining patent-protected sales.

The investment thesis is contingent on the precise timing of generic entry and the ability of the product to maintain a premium price and market share until patent expiry. For potential investors, the decision hinges on the projected net present value of future cash flows, accounting for the anticipated decline in revenue post-generic entry.

Key Takeaways

Jentadueto (linagliptin/metformin) is a mature type 2 diabetes medication with significant patent protection expiring around 2029. It generates substantial revenue, reflecting its established market position in combination therapy. However, the drug faces increasing competition from novel antidiabetic agents and the inevitable market entry of generics post-patent expiry. Investment in Jentadueto relies on maximizing returns during its remaining exclusivity period, with a clear understanding of the revenue decline anticipated with generic competition. The fundamental strengths of its APIs, linagliptin and metformin, support its continued use, but the evolving diabetes treatment landscape and pricing pressures are critical considerations.

Frequently Asked Questions

What is the expected timeline for generic competition for Jentadueto in the U.S.?

Generic competition for Jentadueto in the U.S. is anticipated following the expiration of key patents, primarily U.S. Patent No. 8,575,377, which covers the pharmaceutical composition. This patent is expected to expire in 2029. However, early generic entry can occur through successful patent challenges or through the expiration of statutory exclusivities.

What is the primary mechanism of action for Jentadueto?

Jentadueto combines linagliptin and metformin. Linagliptin is a DPP-4 inhibitor that increases incretin hormone levels, enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Together, they provide dual action for glycemic control.

How does Jentadueto's performance compare to Janumet?

Both Jentadueto and Janumet (sitagliptin/metformin) are leading DPP-4 inhibitor and metformin combination therapies. While their sales figures fluctuate based on market dynamics and regional performance, they occupy a similar competitive space. Janumet has historically held a larger market share, but Jentadueto has maintained a stable revenue stream. Both face similar competitive pressures from generics and newer drug classes.

Are there any known significant safety concerns associated with Jentadueto?

Jentadueto carries the safety profiles of its individual components. Metformin has a known risk of lactic acidosis, particularly in patients with renal impairment, hepatic disease, or heart failure. DPP-4 inhibitors, including linagliptin, have been associated with a small risk of pancreatitis and hypersensitivity reactions. Patients should be monitored for these potential adverse events.

What are the key drivers for future sales growth or decline for Jentadueto?

For the period preceding patent expiry, key drivers for stable sales include physician prescribing habits, patient adherence to combination therapy, and effective marketing by the manufacturer. Post-patent expiry, the primary driver for sales decline will be the introduction and uptake of generic linagliptin/metformin products, coupled with the increasing preference for newer antidiabetic agents with demonstrated cardiovascular and renal benefits.

---

Citations

[1] Boehringer Ingelheim. (2023). Annual Report 2023. [2] U.S. Food & Drug Administration. (n.d.). Orange Book Database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [3] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/patents/search